Elicio Therapeutics (ELTX) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OS Therapies (OSTX) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 53.0% versus a loss of 82.8%. OS Therapies is the larger company by market cap ($42.0 million vs $41.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | OSTX |
|---|---|---|
| Share price | $1.45 | $0.803 |
| Market cap | $41.05M | $42.00M |
| 1-day change | -3.33% | -2.12% |
| YTD return | -81.78% | -42.64% |
| 1-year return | -82.84% | -53.04% |
| 5-year return | -96.13% | — |
| Forward P/E | — | 2.29 |
| EPS (TTM) | $-1.81 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-39.57M | $-28.75M |
| 52-week high | $16.00 | $2.25 |
| 52-week low | $1.25 | $0.58 |
| Distance from 52-week high | -90.94% | -64.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +842.76% | +958.53% |
| Average volume | 324.71K | 722.66K |
| Shares outstanding | 28.31M | 52.30M |
| Employees | 33 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed ELTX by 29.8 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ELTX vs OSTX FAQ
Which is bigger, Elicio Therapeutics or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $41.05M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or OSTX?
OSTX returned -53.04% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.